Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Local Disease Clear all

Conditions: Prostate Cancer
Interventions: Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Recurrent Prostate Cancer
Interventions: FACBC; Drug
Lead sponsor: David M. Schuster, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Gastric Cancer, Stomach Cancer
Interventions: Paclitaxel, Carboplatin, Dexamethasone, Diphenhydramine, Famotidine, Palonosetron, 3D conformal or intensity modulated radiotherapy, Surgical resection, Adjuvant Chemotherapy; Drug · Radiation · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: Femoral Nerve Block; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Carcinoma
Interventions: Tetrathiomolybdate (TM), Radiation, Surgery; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Tibial Plateau Fractures
Interventions: Bupivacain; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hip Arthroplasty, Hip Pain
Interventions: 0.1% Ropivacaine, 0.4% Ropivacaine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Shoulder Pain
Interventions: lidocaine, ethyl chloride, Kenalog; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Breast Cancer
Interventions: filgrastim, pegfilgrastim, lyso-thermosensitive liposomal doxorubicin(Thermodox), hyperthermia treatment; Biological · Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Drug Reaction to Analgesic Nos
Interventions: RX0041 4%, Placebo, RX0041 8%; Drug
Lead sponsor: Pharmaceutical Project Solutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Mount Arlington, New Jersey • Columbia, South Carolina

Conditions: Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: sorafenib tosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Essential Tremor
Interventions: Cala TWO stimulator; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Amputation
Interventions: Ropivacaine 0.2% + nerve stimulator set, Ropivacaine 0.2%; Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Stanford, California • Jacksonville, Florida • Iowa City, Iowa

Conditions: Healthy, Mood Disorders
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Wound Infection, Fractures, Open, Surgical Site Infection
Interventions: Tobramycin Injection; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Lexington, Kentucky • Boston, Massachusetts • Nashville, Tennessee

Conditions: Pruritus, Atopic Dermatitis
Interventions: SRD174 Cream, vehicle cream; Drug · Other
Lead sponsor: Serentis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: phenylephrine and clonidine, punch biopsy; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
Interventions: sodium thiosulfate, examination; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 18 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 68
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more

Conditions: Pain, Acute, Anesthesia, Local, Dermatology/Skin - Other
Interventions: Vibratory Anesthetic Device (VAD); Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Adenocarcinoma, Lung Neoplasms
Interventions: osimertinib, Local Ablative Therapy (LAT); Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer, CIS
Interventions: Not listed
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Phoenix, Arizona • Hialeah, Florida • Vero Beach, Florida + 8 more

Conditions: Tibial Shaft Fracture, Tibial Plateau Fracture
Interventions: Acute injury without compartment syndrome, Acute injury with compartment syndrome, Exertional compartment syndrome; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Head and Neck Cancer, Free Tissue Transfer
Interventions: Ropivicaine, Local Saline Infusion; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3, Bladder Cancer TNM Staging Primary Tumor (T) T3A, Bladder Cancer TNM Staging Primary Tumor (T) T3B, Bladder Cancer TNM Staging Regional Lymph Node (N) N0, Bladder Cancer TNM Staging Regional Lymph Node (N) N1, Bladder Cancer TNM Staging Distant Metastasis (M) M0
Interventions: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]; Drug
Lead sponsor: Taris Biomedical LLC; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 6
States / cities: Hinsdale, Illinois • Rochester, New York • Durham, North Carolina + 3 more

Search by objective public record fields.

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

FACBC for Recurrent Prostate Cancer

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau

Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks

The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Topical Anesthetic for Procedures Through the Nose

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Long-Term Transcutaneous Stimulation and Essential Tremor: A PET Study

Combined Local Anesthetic Blockade and Neuromodulation vs Local Anesthetic Blockade Only for Analgesia After Below-knee Amputation: RCT

Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders

Tobramycin Injection to Prevent Infection in Open Fractures

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Mechanism and Treatment of Sympathetically Maintained Pain

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Variable Perception of Cutaneous Stimulation

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Gene Expression in Lower Extremity Acute Traumatic Compartment Syndrome

Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer